03.06.18
Casey Logan has been appointed vice president, corporate development, Retrophin. Mr. Logan will report to chief operating officer Neil McFarlane, and will be responsible for leading global corporate and business development efforts.
“We are delighted to welcome Casey to the Retrophin team,” said Mr. McFarlane. “This is a pivotal time for the Company, and we look forward to Casey’s contributions as we continue our strides to become a preeminent member of the rare disease community.”
Mr. Logan brings 15 years of experience leading business development, strategic planning and operational activities in the biopharmaceutical industry. Mr. Logan joins the company from Tracon Pharmaceuticals, where he had served as chief business officer since February 2013. At Tracon, Mr. Logan led all strategic, business and corporate development efforts, including the company's IPO in January 2015. Before joining Tracon, Mr. Logan held senior corporate development roles at biopharmaceutical companies Bird Rock Bio and Anadys Pharmaceuticals, Inc., before its acquisition by Roche, and Eli Lilly and Co.
“We are delighted to welcome Casey to the Retrophin team,” said Mr. McFarlane. “This is a pivotal time for the Company, and we look forward to Casey’s contributions as we continue our strides to become a preeminent member of the rare disease community.”
Mr. Logan brings 15 years of experience leading business development, strategic planning and operational activities in the biopharmaceutical industry. Mr. Logan joins the company from Tracon Pharmaceuticals, where he had served as chief business officer since February 2013. At Tracon, Mr. Logan led all strategic, business and corporate development efforts, including the company's IPO in January 2015. Before joining Tracon, Mr. Logan held senior corporate development roles at biopharmaceutical companies Bird Rock Bio and Anadys Pharmaceuticals, Inc., before its acquisition by Roche, and Eli Lilly and Co.
